+1 201 316 9200
+81 (0)3 6264 0600
Europe & Rest of World
+41 61 316 81 11
Preclinical Risk Assessment
Lonza's Cambridge facility is located 50 miles north of London in the county of Cambridgeshire, England. It is a large university town with the river Cam flowing through the center.
Lonza acquired this site in 2009 with the purchase of Algonomics, Inc, a company focused on the early assessment of protein and drug targets. The Cambridge site houses several modern preclinical research laboratories with a wide range of high throughput screening equipment.
Our Applied Protein Services team focuses on a full risk assessment platform for in silico and in vitro services for immunogenicity, stability, humanization, and protein engineering. These technologies include our award winning and patented Epibase™ T cell epitope screening platform along with our proprietary technology platform for structural protein engineering.
Whether you are looking for unwanted immunogenicity in the case of protein therapeutics, or a strong response to a developing vaccine, our protein experts can help optimize your drug target to give you the best chance for clinical success.